Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Co-administration of intravesical bacillus Calmette-Guérin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder
BJU International, Volume 108, No. 7, Year 2011
Notification
URL copied to clipboard!
Description
Objective • To evaluate the efficacy and toxicity of the combination of bacillus Calmette-Guérin (BCG) and interferon α-2B (IFNα-2B) in treating superficial bladder cancer (SBC). The mentioned combination has shown synergism in pre-clinical studies. Patients and Methods • The present study is a single-arm, open-label, single-institution prospective trial. Patients with Ta, T1 or in situ carcinoma and no previous intravesical therapy were included between July 2002 and June 2009. • Patients were treated with weekly intravesical instillation of 27 mg of BCG mixed with 10 million units (MU) of IFNα-2B for six consecutive weeks followed by 3-weekly booster instillations at 3 months if there was no recurrence. • The primary endpoint was disease recurrence. Secondary endpoints were disease progression and toxicity. • Patients were followed-up with cystoscopy and urine cytology every 3 months. Results • In all, 50 patients were included. • At a median follow-up of 55.8 months, 31 (62%) patients were recurrence-free. • Progression to muscle invasion occurred in two (4%) and metastasis occurred in two (4%) patients. • Treatment was well tolerated, with grade III dysuria and frequency occurring in 18 and 14% of patients, respectively, and with 74% of patients being able to complete the maintenance dosage. Conclusion • The combination of BCG and IFNα-2B in the patient population with SBC has similar efficacy and toxicity to BCG monotherapy. © 2011 The Authors. BJU International.
Authors & Co-Authors
Bazarbashi, Mohammad Shouki
Saudi Arabia, Riyadh
King Faisal Specialist Hospital and Research Centre
Soudy, Hussein
Saudi Arabia, Riyadh
King Faisal Specialist Hospital and Research Centre
Abdelsalam, Mahmoud
Saudi Arabia, Riyadh
King Faisal Specialist Hospital and Research Centre
Al-Jubran, Ali
Saudi Arabia, Riyadh
King Faisal Specialist Hospital and Research Centre
Akhtar, Saad
Saudi Arabia, Riyadh
King Faisal Specialist Hospital and Research Centre
Memon, Muhammed Ashraf
Saudi Arabia, Riyadh
King Faisal Specialist Hospital and Research Centre
Aslam, Muhammad Ovais
Saudi Arabia, Riyadh
King Faisal Specialist Hospital and Research Centre
Kattan, Said Abdulghani
Saudi Arabia, Riyadh
King Faisal Specialist Hospital and Research Centre
Shoukri, Mohamed M.
Saudi Arabia, Riyadh
King Faisal Specialist Hospital and Research Centre
Statistics
Citations: 17
Authors: 9
Affiliations: 1
Identifiers
Doi:
10.1111/j.1464-410X.2010.10040.x
ISSN:
14644096
e-ISSN:
1464410X
Research Areas
Cancer
Health System And Policy
Study Design
Cross Sectional Study
Cohort Study